Focused Ultrasound for Brain Metastases: an Update on Global Clinical Trials

Overview

Journal J Neurooncol

Publisher Springer

Date 2023 Nov 1

PMID 37910281

Authors

Yi-Hsiu Chen

David Moore

Cheng-Chia Lee

Yan-Hua Su

Affiliations

Soon will be listed here.

Abstract

Background: Despite advances in immunotherapy and targeted treatments for malignancies of the central nervous system (CNS), the treatment of brain metastases (BMs) remains a formidable challenge, due largely to difficulties in crossing the blood-brain barrier (BBB), drug resistance, and molecular discrepancies. Focused ultrasound (FUS) is a non-invasive tool for BBB breaching, tumor ablation, enhancing drug delivery, promoting the release of tumor biomarkers for liquid biopsy, or the tumor microenvironment disruption. This paper presents a comprehensive review of the current literature related to FUS and its application in the treatment of brain metastasis.

Methods: This review of the current literature via PubMed, Google Scholar, and Clincaltrials.gov focused on clinical trials in which FUS is used in the intracranial treatment of metastatic tumor, glioma, or GBM.

Results: FUS is safe and effective for treatment of primary or metastatic brain tumors. FUS-augmented drug delivery can open BBB to facilitate the transport of chemotherapeutic agents, immunotherapies, and targeted treatments. The integration of FUS with liquid biopsy has considerable potential for early tumor detection, precise gene profiling, and personalized therapy. Sonodynamic therapy can induce tumor cell apoptosis and could potentially be used to enhance the outcomes of other tumor treatments, such as surgery and chemotherapy.

Conclusion: Further work is required to establish FUS as a standard therapy for BMs. FUS has the potential to transform brain tumor treatment, particularly when combined with immunotherapy and targeted therapy as a non-invasive alternative to surgery and radiation therapy.

Citing Articles

Bi-modal confirmation of liposome delivery to the brain after focused ultrasound-induced blood-brain barrier opening.

Payne C, Cressey P, Talianu A, Szychot E, Hargrave D, Thanou M Heliyon. 2024; 10(22):e39972.

PMID: 39624326 PMC: 11609457. DOI: 10.1016/j.heliyon.2024.e39972.

Multidisciplinary management strategies for recurrent brain metastasis after prior radiotherapy: An overview.

Kotecha R, La Rosa A, Brown P, Vogelbaum M, Navarria P, Bodensohn R Neuro Oncol. 2024; 27(3):597-615.

PMID: 39495010 PMC: 11889725. DOI: 10.1093/neuonc/noae220.

Sonodynamic therapy for adult-type diffuse gliomas: past, present, and future.

Scanlon S, Shanahan R, Bin-Alamer O, Bouras A, Mattioli M, Huq S J Neurooncol. 2024; 169(3):507-516.

PMID: 39042302 DOI: 10.1007/s11060-024-04772-6.

Overcoming Treatment Resistance in Medulloblastoma: Underlying Mechanisms and Potential Strategies.

Slika H, Shahani A, Wahi R, Miller J, Groves M, Tyler B Cancers (Basel). 2024; 16(12).

PMID: 38927954 PMC: 11202166. DOI: 10.3390/cancers16122249.

References

Di Giacomo A, Mair M, Ceccarelli M, Anichini A, Ibrahim R, Weller M . Immunotherapy for brain metastases and primary brain tumors. Eur J Cancer. 2022; 179:113-120. DOI: 10.1016/j.ejca.2022.11.012. View

Mo F, Pellerino A, Soffietti R, Ruda R . Blood-Brain Barrier in Brain Tumors: Biology and Clinical Relevance. Int J Mol Sci. 2021; 22(23). PMC: 8657947. DOI: 10.3390/ijms222312654. View

Cacho-Diaz B, Garcia-Botello D, Wegman-Ostrosky T, Reyes-Soto G, Ortiz-Sanchez E, Herrera-Montalvo L . Tumor microenvironment differences between primary tumor and brain metastases. J Transl Med. 2020; 18(1):1. PMC: 6941297. DOI: 10.1186/s12967-019-02189-8. View

Hynynen K, McDannold N, Vykhodtseva N, Jolesz F . Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology. 2001; 220(3):640-6. DOI: 10.1148/radiol.2202001804. View

Hynynen K, McDannold N, Sheikov N, Jolesz F, Vykhodtseva N . Local and reversible blood-brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications. Neuroimage. 2004; 24(1):12-20. DOI: 10.1016/j.neuroimage.2004.06.046. View

Cohen-Inbar O, Xu Z, Sheehan J . Focused ultrasound-aided immunomodulation in glioblastoma multiforme: a therapeutic concept. J Ther Ultrasound. 2016; 4:2. PMC: 4722768. DOI: 10.1186/s40349-016-0046-y. View

Zhu L, Cheng G, Ye D, Nazeri A, Yue Y, Liu W . Focused Ultrasound-enabled Brain Tumor Liquid Biopsy. Sci Rep. 2018; 8(1):6553. PMC: 5919906. DOI: 10.1038/s41598-018-24516-7. View

Patrick J, Nolting M, Goss S, Dines K, Clendenon J, Rea M . Ultrasound and the blood-brain barrier. Adv Exp Med Biol. 1990; 267:369-81. DOI: 10.1007/978-1-4684-5766-7_36. View

Elhelf I, Albahar H, Shah U, Oto A, Cressman E, Almekkawy M . High intensity focused ultrasound: The fundamentals, clinical applications and research trends. Diagn Interv Imaging. 2018; 99(6):349-359. DOI: 10.1016/j.diii.2018.03.001. View

10.

Ter Haar G, Coussios C . High intensity focused ultrasound: physical principles and devices. Int J Hyperthermia. 2007; 23(2):89-104. DOI: 10.1080/02656730601186138. View

11.

Canney M, Khokhlova V, Bessonova O, Bailey M, Crum L . Shock-induced heating and millisecond boiling in gels and tissue due to high intensity focused ultrasound. Ultrasound Med Biol. 2009; 36(2):250-67. PMC: 2815111. DOI: 10.1016/j.ultrasmedbio.2009.09.010. View

12.

Vykhodtseva N, Hynynen K, Damianou C . Histologic effects of high intensity pulsed ultrasound exposure with subharmonic emission in rabbit brain in vivo. Ultrasound Med Biol. 1995; 21(7):969-79. DOI: 10.1016/0301-5629(95)00038-s. View

13.

Meng Y, Pople C, Lea-Banks H, Abrahao A, Davidson B, Suppiah S . Safety and efficacy of focused ultrasound induced blood-brain barrier opening, an integrative review of animal and human studies. J Control Release. 2019; 309:25-36. DOI: 10.1016/j.jconrel.2019.07.023. View

14.

Nance E, Timbie K, Miller G, Song J, Louttit C, Klibanov A . Non-invasive delivery of stealth, brain-penetrating nanoparticles across the blood-brain barrier using MRI-guided focused ultrasound. J Control Release. 2014; 189:123-132. PMC: 4125545. DOI: 10.1016/j.jconrel.2014.06.031. View

15.

Huang Y, Alkins R, Schwartz M, Hynynen K . Opening the Blood-Brain Barrier with MR Imaging-guided Focused Ultrasound: Preclinical Testing on a Trans-Human Skull Porcine Model. Radiology. 2016; 282(1):123-130. PMC: 5179309. DOI: 10.1148/radiol.2016152154. View

16.

McMahon D, OReilly M, Hynynen K . Therapeutic Agent Delivery Across the Blood-Brain Barrier Using Focused Ultrasound. Annu Rev Biomed Eng. 2021; 23:89-113. DOI: 10.1146/annurev-bioeng-062117-121238. View

17.

Liu H, Wai Y, Chen W, Chen J, Hsu P, Wu X . Hemorrhage detection during focused-ultrasound induced blood-brain-barrier opening by using susceptibility-weighted magnetic resonance imaging. Ultrasound Med Biol. 2008; 34(4):598-606. DOI: 10.1016/j.ultrasmedbio.2008.01.011. View

18.

Anastasiadis P, Gandhi D, Guo Y, Ahmed A, Bentzen S, Arvanitis C . Localized blood-brain barrier opening in infiltrating gliomas with MRI-guided acoustic emissions-controlled focused ultrasound. Proc Natl Acad Sci U S A. 2021; 118(37). PMC: 8449371. DOI: 10.1073/pnas.2103280118. View

19.

Carpentier A, Canney M, Vignot A, Reina V, Beccaria K, Horodyckid C . Clinical trial of blood-brain barrier disruption by pulsed ultrasound. Sci Transl Med. 2016; 8(343):343re2. DOI: 10.1126/scitranslmed.aaf6086. View

20.

Yonemori K, Tsuta K, Ono M, Shimizu C, Hirakawa A, Hasegawa T . Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer. Cancer. 2009; 116(2):302-8. DOI: 10.1002/cncr.24735. View